Lipoprotein(a) Management

Patient Identification and Risk Assessment

• Individuals with familial hypercholesterolemia (FH) are at increased risk of cardiovascular disease, according to the European Society of Cardiology 1
• Lipoprotein(a) [Lp(a)] levels above 30 mg/dL (75 nmol/L) indicate increased cardiovascular risk, with levels above 50 mg/dL (125 nmol/L) representing significantly elevated risk requiring more aggressive management, as indicated by the American College of Cardiology, European Atherosclerosis Society, and Canadian Cardiovascular Society 2
• The following table summarizes the thresholds for elevated Lp(a) levels:

2, 1

• Elevated Lp(a) is associated with increased risk of coronary heart disease (CHD) with a risk ratio of 1.13 per standard deviation increase (95% CI 1.09 to 1.18) after adjustment for other risk factors, as noted by 3
• Lp(a) risk is amplified when LDL-C is also elevated, according to the European Heart Journal 1
• Population means and median levels of Lp(a) vary by race/ethnicity, according to the American College of Cardiology 2

Risk Reduction and Management

• Various therapies can reduce Lp(a) levels, including:
• Lifestyle modifications, such as regular physical activity, a Mediterranean or DASH diet, limited alcohol consumption, weight management, and smoking cessation, are recommended to help reduce Lp(a) levels and cardiovascular risk, as suggested by the European Heart Journal and the American College of Cardiology 1, 2, 5, 6
• Low-saturated fat diets may paradoxically raise Lp(a) levels, as noted by the American College of Cardiology 2
• Statins may actually increase Lp(a) levels despite their cardiovascular benefits, as reported by the American College of Cardiology and the European Heart Journal 2, 1

Treatment and Monitoring

• Aggressive LDL-C reduction is recommended, aiming for ≥50% LDL-C reduction from baseline, with high-intensity statin therapy and consideration of PCSK9 inhibitors for additional reduction, as suggested by the American College of Cardiology 2
• Intensive management of other modifiable risk factors, including hypertension control, smoking cessation, diabetes management, and weight reduction in obesity, is essential for reducing cardiovascular risk, as recommended by the European Heart Journal and the American College of Cardiology 1, 2
• Emerging therapies, such as antisense oligonucleotides (e.g., pelacarsen) and small interfering RNA agents (e.g., olpasiran), can reduce Lp(a) by >80%, showing significant promise in clinical trials, as noted by the American College of Cardiology 7, 2
• Consider calculating risk-weighted ApoB using the formula: Risk-weighted ApoB = ApoB + (Lp(a) × 6), as suggested by the National Lipid Association 2
• Monitor for medication side effects, such as those associated with statins and PCSK9 inhibitors, as recommended by the European Atherosclerosis Society 2